公告称，主要由于集团铝合金产品和氧化铝产品销售价格较2023年同期上涨，且氧化铝产品销售数量亦有所增加；同时，集团主要原材料煤炭和阳极炭块的采购价格较2023年同期下降。受益于该等积极因素，集团前述产品毛利较2023年同期实现大幅增加。The important announcements for Hong Kong stocks today are as follows:
1) Company News
$CHINAHONGQIAO (01378.HK)$It is expected that the net income for the year ending December 31, 2024, may increase by about 95% year-on-year.
The announcement states that primarily due to the sales prices of the group's Aluminum alloy products and alumina products rising compared to the same period in 2023, and an increase in the sales quantity of alumina products; simultaneously, the procurement prices of the group's main raw materials, Coal and anode carbon blocks, have decreased compared to the same period in 2023. Benefiting from these positive factors, the gross profit of the group's aforementioned products has significantly increased compared to the same period in 2023.
$CHINA COAL (01898.HK)$In the first 11 months, the sales volume of Commodity Coal was 0.256 billion tons, a year-on-year decrease of 1.9%; the sales volume in November was 25.8 million tons, an increase of 11.4% year-on-year.
$CANGGANGRAILWAY (02169.HK)$Discussions are actively underway with several large state-owned transportation enterprises regarding strategic cooperation opportunities related to the Huanghua Port Rail Transportation System.
$TIANJIN CAPITAL (01065.HK)$Plans to sell 100% equity of Tianjin Capital Environmental Protection (Hong Kong) for 29.9735 million yuan.
iFLYTEK Medical Technology (02506.HK): IPO from December 18 to December 23.
$INNOSCIENCE (02577.HK)$Plans to globally issue 45.364 million shares.
Health Road (02587.HK): IPO from December 18 to December 23.
$GUOLIAN SEC (01456.HK)$: The issuance of shares to purchase assets and raise matching funds has been approved by the Shanghai Stock Exchange's restructuring committee.
$CARDIOFLOW-B (02160.HK)$: VITAFLOW LIBERTY® FLEX has been approved for registration by the National Medical Products Administration.
$R&F PROPERTIES (02777.HK)$: The hearing regarding R&F PROPERTIES Hong Kong and Zhaoxi's request has been postponed until March 31, 2025.
$IMMUNEONCO-B (01541.HK)$: The Phase IB clinical trial of IMM0306 for treating neuromyelitis optica spectrum disorders has completed dosing for the first patient.
$CHANJET (01588.HK)$: It is recommended to implement full circulation of H shares.
$GOLDLION HOLD (00533.HK)$: The chairman Zeng Zhiming proposed privatization at a premium of about 24.85%, resuming trading on December 18.
2) Financing and repurchase dynamics.
$SENSETIME-W (00020.HK)$: Completed the placement of a total of 1.865 billion shares.
$TENCENT (00700.HK)$: Invested 0.703 billion Hong Kong dollars to repurchase 1.74 million shares at a repurchase price of 401.8-407 Hong Kong dollars.
$AIA (01299.HK)$Invested 0.455 billion Hong Kong dollars to repurchase 8.272 million shares at a repurchase price of 54.55-55.3 Hong Kong dollars.
$COSCO SHIP HOLD (01919.HK)$Invested 25.3657 million Hong Kong dollars to repurchase 2.032 million shares at a repurchase price of 12.40-12.52 Hong Kong dollars.
$TIMES ELECTRIC (03898.HK)$Invested 19.9639 million Hong Kong dollars to repurchase 0.6514 million shares at a repurchase price of 30.15-31.25 Hong Kong dollars.
3) Issue of new shares.
$CH BIOTECH SER (08037.HK)$Proposed to issue 6 million US dollars in convertible bonds.
$REPT BATTERO (00666.HK)$Subscribed for 1.476 million shares of Zhongli shares A-share IPO strategic placement.
$STERLING GP (01825.HK)$Proposed to place up to 57.6 million shares at a discount of approximately 18.6%.
Editor/danial
